UroGen Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.About URGN
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology.
CEOElizabeth Barrett
CEOElizabeth Barrett
Employees235
Employees235
HeadquartersPrinceton, New Jersey
HeadquartersPrinceton, New Jersey
Founded2004
Founded2004
Employees235
Employees235
URGN Key Statistics
Market cap927.28M
Market cap927.28M
Price-Earnings ratio-5.73
Price-Earnings ratio-5.73
Dividend yield—
Dividend yield—
Average volume629.31K
Average volume629.31K
High today—
High today—
Low today—
Low today—
Open price$21.53
Open price$21.53
Volume0.00
Volume0.00
52 Week high$30.00
52 Week high$30.00
52 Week low$3.42
52 Week low$3.42
Stock Snapshot
The current UroGen Pharma(URGN) stock price is $19.77, with a market capitalization of 927.28M. The stock trades at a price-to-earnings (P/E) ratio of -5.73.
During the trading day, UroGen Pharma(URGN) stock saw an opening price of $21.53, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 629.31K.
The stock's 52-week range extends from a low of $3.42 to a high of $30.00.
The stock's 52-week range extends from a low of $3.42 to a high of $30.00.
URGN News
Simply Wall St 1d
Assessing UroGen Pharma Valuation After ZUSDURI Secures Permanent J CodeUroGen Pharma (URGN) shares are in focus after the company reported that its bladder cancer therapy ZUSDURI now has a permanent J code (J9282), effective Januar...
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.